October 22, 2013Novozymes Biopharma announces collaboration with Almac in drug manufacture, half-life extension and targeting technologies
July 18, 2013Novozymes Biopharma's Hyasis increases in vitro drug release from 10 minutes to 15 hours
July 18, 2013Novozymes Biopharma's Hyasis increases drug release of tramadol hydrochloride from 1.9 to 7.5 hours
May 28, 2013Novozymes Biopharma to showcase world leading products at CPhI China
May 20, 2013Novozymes Biopharma's recombinant albumin helps innovative dry eye therapy move into clinical trials
February 27, 2013Novozymes Biopharma's rAlbumin approved in Japan as MAQUET expands into new market
February 21, 2013Novozymes Biopharma shortlisted for the Medilink UK National awards
February 12, 2013Novozymes Biopharma announces research agreement with EpiVax to advance pioneering treatment of autoimmune diseases
January 14, 2013Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name
Sally VernonCustomer Communications ManagerTel.: +44 115 955 3355Fax: +44 115 955 1299Click here to email
Thomas Steenbech BomhoffSenior Manager of Investor RelationsTel.: +1 919 494 3483Fax: +1 919 494 3473Click here to email
Novozymes Biopharma is a part of Novozymes A/S and is listed on the NASDAQ, trading as NZYM B.
Copyright © 2011 Novozymes. All rights reserved.